WenTongGanPi decoction alleviates diarrhea-predominant irritable bowel syndrome by improving intestinal barrier

被引:2
|
作者
Li, Yaoguang [1 ]
Chen, Yangyang [2 ]
Liao, Zhengyue [3 ]
Liu, Yixin [3 ]
Liu, Chenhao [4 ]
Yang, Wenjing [3 ]
Bai, Jing [3 ]
Huang, Xinggui [4 ]
Hao, Yule [4 ]
Liu, Sijing [1 ,3 ]
Liu, Yi [1 ]
机构
[1] Chengdu Univ Tradit Chinese Med, Coll Clin Med, Chengdu 611103, Peoples R China
[2] Chengdu Univ Tradit Chinese Med, Coll Pharm, Chengdu 611103, Peoples R China
[3] Chengdu Univ Tradit Chinese Med, Coll Med Technol, Chengdu 611103, Peoples R China
[4] Chengdu Univ Tradit Chinese Med, Coll Basic Med Sci, Chengdu 610075, Peoples R China
关键词
WenTongGanPi decoction; Irritable bowel syndrome; Diarrhea; MAPK signal pathway; Intestinal barrier; Gut microbiota; CHAIN FATTY-ACIDS; Q-TOF-MS/MS; METABOLITE; MICROBIOTA; MAPK;
D O I
10.1016/j.jep.2024.118544
中图分类号
Q94 [植物学];
学科分类号
071001 ;
摘要
Ethnopharmacological relevance: WenTongGanPi Decoction (WTGPD) is a representative medical practice of the Fuyang School of Traditional Chinese Medicine (TCM), which originated from the classical Lu's Guizhi method. WTGPD places emphasis on the balance and functionality of yang qi, and is effective in treating TCM symptoms related to liver qi stagnation and spleen yang deficiency. In TCM, diarrhea-predominant irritable bowel syndrome (IBS-D) is often diagnosed as liver depression and spleen deficiency, and the use of WTGPD has shown significant therapeutic effect. However, the underlying mechanism of WTGPD treating IBS-D remains unclear. Aim of the study: To explore the effect and mechanism of WTGPD in the treatment of IBS-D. Materials and methods: An IBS-D model with liver depression and spleen deficiency was constructed by chronic immobilization stress stimulation and sennae folium aqueous gavage. The impact of WTGPD on IBS-D rats was evaluated through measurements of body weight, fecal water content, and abdominal withdrawal reflex (AWR). Intestinal permeability was assessed using hematoxylin-eosin (HE), alcian blue-periodic acid schiff (AB-PAS), immunofluorescence (IF) staining, and quantitative real-time PCR (qRT-PCR). The components of WTGPD were analyzed using UPLC-Q-TOF-MS. The underlying mechanisms were investigated through network pharmacology, transcriptomics sequencing, western blot (WB), molecular docking, and 16S rRNA sequencing. Results: WTGPD treatment effectively alleviated diarrhea and abnormal pain in IBS-D rats (P P < 0.05). It enhanced the intestinal barrier function by improving colonic structure and increasing the expression of tight junction proteins (P P < 0.05). A total of 155 components were identified in WTGPD. Both network pharmacology and transcriptomics sequencing analysis highlighted MAPK as the key signaling pathway in WTGPD's anti-IBS-D effect. The WB results showed a significant decrease in p-p38, p-ERK and p-JNK expression after WTGPD treatment (P P < 0.0001). Guanosine, adenosine and hesperetin in WTGPD may be involved in regulating the phosphorylation of p38, ERK and JNK. Additionally, WTGPD significantly enhanced microbial diversity and increased the production of colonic valeric acid in IBS-D rats (P P < 0.01). Conclusion: In conclusion, our findings suggest that WTGPD can effectively alleviate IBS-D and improve intestinal barrier likely via inhibiting MAPK signal pathway and improving micobial dysbiosis.
引用
收藏
页数:15
相关论文
共 50 条
  • [21] Pharmacokinetic drug evaluation of rifaximin for treatment of diarrhea-predominant irritable bowel syndrome
    Bruzzese, Eugenia
    Pesce, Marcella
    Sarnelli, Giovanni
    Guarino, Alfredo
    EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2018, 14 (07) : 753 - 760
  • [22] Eluxadoline in the treatment of diarrhea-predominant irritable bowel syndrome. The SEPD perspective
    Vera, Isabel
    Judez, Javier
    REVISTA ESPANOLA DE ENFERMEDADES DIGESTIVAS, 2017, 109 (11) : 788 - 793
  • [23] Update on the Management of Diarrhea-Predominant Irritable Bowel Syndrome: Focus on Rifaximin and Eluxadoline
    Rivkin, Anastasia
    Rybalov, Sergey
    PHARMACOTHERAPY, 2016, 36 (03): : 300 - 316
  • [24] Luminal and mucosal-associated intestinal microbiota in patients with diarrhea-predominant irritable bowel syndrome
    Carroll, Ian M.
    Chang, Young-Hyo
    Park, Jiwon
    Sartor, R. Balfour
    Ringel, Yehuda
    GUT PATHOGENS, 2010, 2
  • [25] Luminal and mucosal-associated intestinal microbiota in patients with diarrhea-predominant irritable bowel syndrome
    Ian M Carroll
    Young-Hyo Chang
    Jiwon Park
    R Balfour Sartor
    Yehuda Ringel
    Gut Pathogens, 2
  • [26] Duodenal and rectal mucosal microbiota related to small intestinal bacterial overgrowth in diarrhea-predominant irritable bowel syndrome
    Yang, Min
    Zhang, Lei
    Hong, Gaichao
    Li, Ying
    Li, Gangping
    Qian, Wei
    Xiong, Hanhua
    Bai, Tao
    Song, Jun
    Hou, Xiaohua
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2020, 35 (05) : 795 - 805
  • [27] Characterization of kynurenine pathway in patients with diarrhea-predominant irritable bowel syndrome
    Li, Pingping
    Zheng, Jimin
    Bai, Yun
    Wang, Dingxin
    Cui, Zijin
    Li, Yueqin
    Zhang, Jian
    Wang, Yuzhen
    EUROPEAN JOURNAL OF HISTOCHEMISTRY, 2020, 64 : 14 - 21
  • [28] Clinical study on acupuncture in treating diarrhea-predominant irritable bowel syndrome
    Liu H.-R.
    Yang Y.
    Wu H.-G.
    Journal of Acupuncture and Tuina Science, 2008, 6 (6) : 360 - 362
  • [29] Evaluation of Crofelemer in the Treatment of Diarrhea-Predominant Irritable Bowel Syndrome Patients
    Mangel, Allen W.
    Chaturvedi, Pravin
    DIGESTION, 2008, 78 (04) : 180 - 186
  • [30] Leaky Gut in Patients with Diarrhea-Predominant Irritable Bowel Syndrome and Inactive Ulcerative Colitis
    Gecse, Krisztina
    Roka, Richard
    Sera, Terez
    Rosztoczy, Andras
    Annahazi, Anita
    Izbeki, Ferenc
    Nagy, Ferenc
    Molnar, Tamas
    Szepes, Zoltan
    Pavics, Laszlo
    Bueno, Lionel
    Wittmann, Tibor
    DIGESTION, 2012, 85 (01) : 40 - 46